Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Titan Pharmaceuticals Inc TTNP

Healthcare

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TTNP)

Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine

Marketwired February 19, 2016

Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction

PR Newswire January 12, 2016

Trading of Titan Pharmaceuticals Stock Halted Today

Marketwired January 12, 2016

Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors

GlobeNewswire January 8, 2016

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) FDA Decision Approaching - Brief Report

Accesswire January 6, 2016

Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction

Marketwired December 9, 2015

Braeburn Pharmaceuticals And Titan Pharmaceuticals Announce Date Of FDA Advisory Committee Review Of Probuphine For Opioid Addiction

PR Newswire December 9, 2015

Equity Market Movement at a Glance - Research on Ultralife, First Acceptance, Titan Pharmaceuticals and Gencor Industries

Accesswire December 2, 2015

Titan Pharmaceuticals Announces FDA's Acceptance of Resubmission of New Drug Application for Probuphine

Marketwired September 28, 2015

Titan Pharmaceuticals Announces Reverse Stock Split

Marketwired September 28, 2015

Braeburn Announces FDA's Acknowledgment of Receipt of Probuphine® NDA Resubmission; Agency Action Expected by February 27, 2016

PR Newswire September 28, 2015

Titan Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference

Marketwired September 3, 2015

Titan Pharmaceuticals Announces Resubmission of the New Drug Application for Probuphine for the Maintenance Treatment of Opioid Addiction

Marketwired August 31, 2015

Titan Pharmaceuticals Reports Second Quarter 2015 Financial Results

Marketwired August 13, 2015

Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2015 Financial Results

Marketwired August 11, 2015

Titan Pharmaceuticals Presents Nonclinical Data Supporting Use of ProNeura Drug Delivery Platform in Parkinson's Disease

Marketwired June 17, 2015

Titan Pharmaceuticals to Present at the BIO International Convention

Marketwired June 10, 2015

Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction

Marketwired June 8, 2015

Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction

PR Newswire June 8, 2015

Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction

Marketwired June 5, 2015